Drug Interactions between Abraxane and gemcitabine
This report displays the potential drug interactions for the following 2 drugs:
- Abraxane (paclitaxel protein-bound)
Interactions between your drugs
gemcitabine PACLitaxel protein-bound
Applies to: gemcitabine and Abraxane (paclitaxel protein-bound)
Using PACLitaxel protein-bound together with gemcitabine may decrease the effects of gemcitabine. Contact your doctor if your condition changes. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
PACLitaxel protein-bound food
Applies to: Abraxane (paclitaxel protein-bound)
Grapefruits and grapefruit juice may increase the blood levels and effects of PACLitaxel protein-bound. This can increase the risk of side effects such as nausea, diarrhea, hair loss, muscle pain or weakness, nerve damage, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Contact your doctor if you experience paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, pain or burning during urination, vision problems, and/or numbness, burning or tingling in your hands and feet. You may need a dose adjustment and/or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
|No interaction information available.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.